By Noel Randewich and Lisa Pauline Mattackal (Reuters) -Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Eli Lilly's orforglipron shows promising Phase ... % gain in the previous session (we told you about that on the last Wall Street Lunch.) Pershing Square disclosed that it acquired 4.1% of the ...

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose ...

Several Wall Street analysts said they expected Eli Lilly would set a sticker price under $1,000 a month for orforglipron, lower than the sticker prices of Zepbound ($1,086) and Wegovy ($1,349 ...